Factors favouring palliative treatment multidisciplinary decisions for newly diagnosed visceral and soft tissue sarcomas

Clin Oncol (R Coll Radiol). 2008 Sep;20(7):523-7. doi: 10.1016/j.clon.2008.03.014. Epub 2008 Apr 28.

Abstract

Aims: The multidisciplinary medical decision-making process is a key element of the clinical management of cancers, especially rare cancers such as visceral and soft tissue sarcomas. One of the most important decisions stated is to discriminate patients considered for palliative-intent treatment. The aim of this retrospective study was to establish the rationale parameters that justify this decision for newly diagnosed sarcomas.

Patients and methods: From a retrospective cohort of 341 patients we investigated the parameters justifying a palliative-intent strategy decision in univariate and multivariate analyses, based on the logistic regression model. We also measured the effect of this decision on overall survival using the Cox model.

Results: Seventy-one of 341 patients (20%) were considered for a palliative-intent strategy. In multivariate analysis, five variables justified this decision: contraindication for general anaesthesia (adjusted odds ratio 10.5), head and neck location (odds ratio 3.7), visceral sarcoma (odds ratio 2.8), tumour size over 8 cm (odds ratio 3.5) and presence of metastasis (odds ratio 39.5). In the Cox model we found that two independent factors were associated with poor outcome: grade 3 (hazard ratio 2.7) and palliative-intent strategy (hazard ratio 3.3).

Conclusions: About 20% of newly diagnosed sarcomas were considered for palliative strategy by multidisciplinary committee. This decision was based on rationale parameters and had an intrinsic prognostic value.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Decision Making*
  • Female
  • Humans
  • Interdisciplinary Communication
  • Logistic Models
  • Male
  • Middle Aged
  • Palliative Care / psychology*
  • Prognosis
  • Proportional Hazards Models
  • Retrospective Studies
  • Soft Tissue Neoplasms / mortality
  • Soft Tissue Neoplasms / pathology
  • Soft Tissue Neoplasms / therapy*
  • Survival Analysis